NasdaqCM - Delayed Quote USD

Cue Biopharma, Inc. (CUE)

1.5600 -0.0200 (-1.27%)
At close: 4:00 PM EDT
1.5200 -0.04 (-2.56%)
After hours: 4:05 PM EDT

Key Executives

Amounts are as of December 31, 2022 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
NameTitlePayExercisedYear Born
Mr. Daniel R. Passeri J.D., M.Sc. CEO & Director 985.72k -- 1961
Dr. Anish Suri Ph.D. President & Chief Scientific Officer 641.98k -- 1974
Ms. Kerri-Ann Millar Chief Financial Officer 559.03k -- 1970
Dr. Ronald D. Seidel III, Ph.D. Co-Founder 316.63k -- 1976
Dr. Rodolfo J. Chaparro Co-Founder & Senior Advisor 316.63k -- 1973
Dr. Steven C. Almo Co-Founder and Chairman of Scientific & Clinical Advisory Board -- -- 1961
George B. Zavoico Ph.D. VP of Investor Relations & Corporate Development -- -- --
Mr. Colin G. Sandercock J.D., MSE Senior VP, General Counsel & Secretary 381.42k -- 1957
Dr. Matteo Levisetti M.D. Chief Medical Officer -- -- 1969

Cue Biopharma, Inc.

40 Guest Street
Boston, MA 02135
United States
617 949 2680 https://www.cuebiopharma.com
Sector: 
Healthcare
Industry: 
Biotechnology
Full Time Employees: 
53

Description

Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops a novel class of injectable therapeutics to selectively engage and modulate targeted, disease relevant T cells directly within the patient's body. Its lead drug product candidate is CUE-101 for the treatment of human papilloma virus (HPV16+)-driven recurrent/metastatic head and neck cancer. The company is also developing CUE-102 targets Wilms' Tumor 1 protein in various cancers; CUE-103, a CUE-100 series drug product candidate; and Neo-STAT and RDI-STAT programs outside of oncology, including CUE-200, CUE-300, and CUE-400 series. It has collaboration agreements with LG Chem, Ltd. for the development of Immuno-STATs focused in the field of oncology; strategic collaboration and option agreement with Ono Pharmaceutical Co., Ltd. to advance CUE-401 for the treatment of autoimmune and inflammatory diseases; and license agreement with Albert Einstein College of Medicine. The company was formerly known as Imagen Biopharma, Inc. and changed its name to Cue Biopharma, Inc. in October 2016. Cue Biopharma, Inc. was incorporated in 2014 and is headquartered in Boston, Massachusetts.

Corporate Governance

Cue Biopharma, Inc.’s ISS Governance QualityScore as of April 1, 2024 is 6. The pillar scores are Audit: 4; Board: 7; Shareholder Rights: 4; Compensation: 8.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Recent Events

Upcoming Events

May 07, 2024 - May 13, 2024
Cue Biopharma, Inc. Earnings Call

Related Tickers

CGTX Cognition Therapeutics, Inc.
1.8400
0.00%
 
TFFP TFF Pharmaceuticals, Inc.
3.1100
-0.96%
 
AZTR Azitra, Inc.
0.1950
+2.74%
 
GANX Gain Therapeutics, Inc.
3.1800
+0.95%
 
INAB IN8bio, Inc.
1.0300
-1.90%
 
ACET Adicet Bio, Inc.
1.9500
-3.70%
 
ALRN Aileron Therapeutics, Inc.
4.7400
-5.20%
 
LIFE aTyr Pharma, Inc.
1.6000
-1.23%
 
APTO Aptose Biosciences Inc.
1.2310
-3.07%
 
CRVS Corvus Pharmaceuticals, Inc.
1.4000
-0.71%